小児免疫性血小板減少症診療ガイドライン　2022年版

出版社： 診断と治療社
著者：
発行日： 2022-06-30
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784787825544
電子書籍版： 2022-06-30 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

日本小児血液・がん学会による公式ガイドライン．出生直後から成人までに血小板のみの減少から出血症状を呈する疾患は，造血器腫瘍，感染に伴うもの，遺伝性疾患まで実に様々である．本ガイドラインは，小児と成人における免疫性血小板減少症の病態と治療の相違点を明確に示し，正しい診断と適切な治療法の選択ができるよう記載されている．専門医のみならず，小児科や一般内科の現場で活用しやすい包括的かつ実践的な1冊．

目次

  • Chapter 1 小児免疫性血小板減少症診療ガイドライン2022年版
    I 総説 免疫性血小板減少症（ITP）とは？

    II CQ1 小児ITP患者の治療方針の決定に必要な分類と検査および治療介入の目安は？
     CQ1.1 血小板減少症の定義および用語・分類は？
     CQ1.2 治療方針の決定に必要な検査は？
     CQ1.3 重症度をどのように評価するか？
     CQ1.4 患者および家族の健康に関連した生活の質（HRQoL）評価を治療方針に反映すべきか？
     CQ1.5 治療介入の目安は？

    III CQ2 小児ITP患者に対するファーストラインの治療は？
     CQ2.1 新規診断ITP患者に副腎皮質ステロイド治療を行うか？
     CQ2.2 新規診断ITP患者に免疫グロブリン静注療法（IVIG）を行うか？
     CQ2.3 新規診断ITP患者に副腎皮質ステロイド治療と免疫グロブリン静注療法（IVIG）の
    　　　　　どちらを選ぶか？
     CQ2.4 新規診断ITP患者に対するファーストラインの治療として，
    　　　　　トロンボポエチン受容体作動薬（TPO-RA）またはリツキシマブを使うか？
     CQ2.5 新規診断ITP患者に対して，副腎皮質ステロイド治療や
    　　　　　免疫グロブリン静注療法（IVIG）以外に配慮すべきことがあるか？
     CQ2.6 乳児の新規診断ITP患者のファーストラインの治療は？
     CQ2.7 無治療経過観察中の持続性および慢性ITP患者が急性増悪した場合や
    　　　　　再発（再帰）性ITP患者の治療は？

    IV CQ3 小児ITP患者に対するセカンドラインの治療は？
     CQ3.1 セカンドラインの治療としてトロンボポエチン受容体作動薬（TPO-RA）を投与するか？
     CQ3.2 セカンドラインの治療としてリツキシマブを投与するか？
     CQ3.3 セカンドラインの治療として脾臓摘出術（脾摘）を行うか？
     CQ3.4 セカンドラインの治療のなかで何が優先されるか？
     CQ3.5 エルトロンボパグとロミプロスチムのどちらを優先すべきか？

    V CQ4 ワクチンおよびヘリコバクター・ピロリ感染に関連したITP
     CQ4.1 ワクチン接種に関連したITPの特徴は？
     CQ4.2 小児の慢性ITP患者におけるヘリコバクター・ピロリの検査と除菌は？

    VI CQ5 脾臓摘出術（脾摘）後の有効な感染管理は？
     CQ5.1 脾摘を行う場合のワクチン接種は？
     CQ5.2 脾摘後の予防的抗菌薬投与は？

    VII CQ6 副腎皮質ステロイドやリツキシマブを投与した場合に推奨されるワクチン接種の方法は？
     CQ6.1 副腎皮質ステロイド治療中の小児に対する不活化ワクチン接種は有用か？
     CQ6.2 副腎皮質ステロイド治療中の小児に対する生ワクチン接種は有用か？
     CQ6.3 リツキシマブ投与後の小児に対するワクチン接種は有用か？

    VIII CQ7 ITP合併妊婦から出生した新生児の管理は？
     CQ7.1 ITP合併妊婦から出生した新生児の検査は？
     CQ7.2 ITP合併妊婦から出生した新生児の治療は？

    IX CQ8 緊急時の治療は？
     CQ8.1 緊急時の治療として免疫グロブリン静注療法（IVIG）は有用か？
     CQ8.2 緊急時の治療として副腎皮質ステロイド治療は有用か？
     CQ8.3 緊急時の治療として血小板輸血は有用か？
     CQ8.4 緊急時の治療としてトロンボポエチン受容体作動薬（TPO-RA）は有用か？
     CQ8.5 緊急時の治療として脾臓摘出術（脾摘）は有用か？

    X CQ9 小児ITP患者の生活管理上の注意点は？
     CQ9.1 ITP患者において，運動制限は必要か？
     CQ9.2 ITP患者において，出血リスクが高いスポーツへの参加は可能か？
     CQ9.3 ITP患者において，出血リスクが中間のスポーツへの参加は可能か？
     CQ9.4 ITP患者において，出血リスクが低いスポーツへの参加は可能か？ 
     CQ9.5 思春期のITP患者における月経の出血頻度や出血量のコントロールに，
    　　　　　ホルモン療法は有効か？
     CQ9.6 思春期のITP患者における月経の出血頻度や出血量のコントロールに，
    　　　　　抗線溶薬の投与は有効か？
     CQ9.7 思春期のITP患者における月経過多では，鉄剤の補充が有効か？

    XI CQ10 小児ITP患者に対するサードライン以降の治療は？
     CQ10 小児ITPのサードライン以降で推奨される治療は？

    Chapter 2 システマティックレビュー（SR）ダイジェスト
    文献検索式：CQ2 小児ITP患者に対するファーストラインの治療は？
    文献検索式：CQ3 小児ITP患者に対するセカンドラインの治療は？
    付録 小児難治性ITP治療ガイド2019
    和文索引
    欧文－数字索引

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter 1 小児免疫性血小板減少症診療ガイドライン2022年版

P.8 掲載の参考文献
1) Cooper N, Bussel J : The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133 : 364-374, 2006.
PubMed
2) Berchtold P, McMillan R, Tani P, et al. : Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura. Blood 74 : 1600-1602, 1989.
PubMed
3) Taub JW, Warrier I, Holtkamp C, et al. : Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura. Am J Hematol 48 : 104-107, 1995.
PubMed
4) Chang M, Nakagawa PA, Williams SA, et al. : Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102 : 887-895, 2003.
PubMed
5) Winiarski J. : Platelet antigens in varicella associated thrombocytopenia. Arch Dis Child 65 : 137-139, 1990.
PubMed
6) Schmidt DE, Lakerveld AJ, Heitink-Polle KMJ, et al. : Anti-platelet antibody immunoassays in childhood immune thrombocytopenia : a systematic review. Vox Sang 115 : 323-333, 2020.
PubMed
7) Porcelijn L, Huiskes E, Oldert G, et al. : Detection of platelet autoantibodies to identify immune thrombocytopenia : state of the art. Br J Haematol 182 : 423-426, 2018.
PubMed
8) Kosugi S, Tomiyama Y, Honda S, et al. : Anti-alphavbeta3 antibodies in chronic immune thrombocytopenic purpura. Thromb Haemost 85 : 36-41, 2001.
PubMed
9) Liu B, Zhao H, Poon MC, et al. : Abnormality of CD4 (+) CD25 (+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78 : 139-143, 2007.
PubMed
10) Yu J, Heck S, Patel V, et al. : Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112 : 1325-1328, 2008.
PubMed
11) Kuwana M, Kaburaki J, Ikeda Y : Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura : role in production of antiplatelet autoantibody. J Clin Invest 102 : 1393-1402, 1998.
PubMed
12) Olsson B, Andersson PO, Jernas M, et al. : T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 : 1123-1124, 2003.
PubMed
13) Houweijl EJ, Blom NR, van der Want JJL, et al. : Ultrastructual study shows morphologic features of apoptosis and para-apoptosis in megakaryocyotes from patients with idiopathic thrombocyotopenic purpura. Blood 103 : 500-506, 2004.
 
14) Emmerich F, Bal G, Barakat A, et al. : High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 136 : 309-314, 2007.
PubMed
15) Rosser EC, Mauri C : Regulatory B cells : origin, phenotype, and function. Immunity 42 : 607-612, 2015.
PubMed
16) Arnold DM, Nazy I, Clare R, et al. : Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding : lessons from the McMaster ITP Registry. Blood Adv 1 : 2414-2420, 2017.
PubMed
17) Eto K, Kunishima S : Linkage between the mechanisms of thrombocytopenia and thrombopoiesis. Blood 127 : 1234-1241, 2016.
PubMed
18) 笹原洋二, 國島伸治, 石黒精, 他 (日本小児血液・がん学会血小板委員会) : 先天性血小板減少症・異常症の診療ガイド. 日小児血がん会誌 58 : 253-262, 2021.
Medical*Online
19) 石黒精, 内山徹, 國島伸治 : 先天性血小板減少症・異常症の新しい診断・登録・検体保存体制. 日小児血がん会誌 57 : 227-234, 2020.
Medical*Online
20) Kuhne T, Imbach P, Bolton-Maggs PH, et al. : Newly diagnosed idiopathic thrombocytopenic purpura in childhood : an observation study. Lancet 358 : 2122-2125, 2001.
 
21) Shirahata A, Fujisawa K, Ishii E, et al. : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
22) Zeller B, Helgestad J, Hellebostad M, et al. : Immune thrombocytopenic purpura in childhood in Norway : a prospective, population-based registration. Pediatr Hematol Oncol 17 : 551-558, 2000.
PubMed
23) Higashigawa M, Maeyama T, Yoshino A, et al. : Incidence of childhood primary immune thrombocytopenic purpura. Pediatr Int 57 : 1041-1043, 2015.
PubMed
24) Kubota M, Adachi S, Usami I, et al. : Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children : a retrospective multi-center study. Int J Hematol 91 : 252-257, 2010.
PubMed
25) Neunert CE, Buchanan GR, Imbach P, et al. : Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia : data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 121 : 4457-4462, 2013.
 
26) Heitink-Polle KMJ, Nijsten J, Boonacker CW, et al. : Clinical and laboratory predictors of chronic immune thrombocytopenia in children : a systematic review and meta-analysis. Blood 124 : 3295-3307, 2014.
PubMed
27) Kuhne T, Buchanan GR, Zimmerman S, et al. : A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the International Childhood ITP Study group. J Pediatr 143 : 605-608, 2003.
 
28) Bennett CM, Neunert C, Grace RF, et al : Predictors of remission in children with newly diagnosed immune thrombocytopenia : Data from the International Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 65 : doi : 10.1002/pbc.26736, 2018.
 
29) Neunet CE, Buchanan GR, Imbach P, et al. : Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112 : 4003-4008, 2008.
 
30) Iyori H, Bessho F, Ookawa H, et al. : Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol 79 : 691-695, 2000.
PubMed
31) Psaila B, Petrovic A, Page LK, et al. : Intracranical hemorrhage (ICH) in children with immune thrombocytopenia (ITP) : study of 40 cases. Blood 114 : 4777-4783, 2009.
 
32) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
33) Shirahata A, Fujisawa K, Ishii E, et al. : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
34) Higashigawa M, Yamamoto T, Yoshino A, et al. : Evaluation of Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura. Pediatr Int 53 : 701-705, 2011.
PubMed
35) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
36) Provan D, Arnold DM, Bussel JB, et al. : Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3 : 3780-3817, 2019.
PubMed
37) Grainger JD, Rees JL, Reeves M, et al. : Changing trends in the UK management of childhood ITP. Ach Dis Child 97 : 8-11, 2012.
 
38) Heitink-Polle KMJ, Uiterwaal CSPM, Porcelijn L. et al. : Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia : a randomized controlled trial. Blood 132 : 883-891, 2018.
PubMed
39) Buchanan GR, Adix L : Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 141 : 683-688, 2002.
PubMed
40) Schoettler M, Graham D, Tao W, et al. : Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMPR). Pediatr Blood Cancer 64 : 10.1002/pbc.26303, 2017.
 
41) Wood JH, Partrick DA, Hays T, et al. : Predicting response to splenectomy in children with immune thrombocytopenic purpura. J Pediatr Surg 45 : 140-144, 2010.
PubMed
42) Bhatt NS, Bhatt P, Donda K, et al. : Temporal trends of splenectomy in pediatric hospitalizations with immune thrombocytopenia. Pediatr Blood Cancer 65 : e27072, 2018.
PubMed
43) Thomsen RW, Schoonen WM, Farkas DK, et al. : Risk for hospital contact with infection in patients with splenectomy : a population-based cohort study. Ann Intern Med 151 : 546-555, 2009.
PubMed
44) Crary SE, Buchanan GR : Vascular complications after splenectomy for hematologic disorders. Blood 114 : 2861-2868, 2009.
PubMed
45) Di Sabatino A, Carsetti R, Corazza GR. : Post-splenectomy and hyposplenic states. Lancet 378 : 86-97, 2011.
PubMed
46) Theilacker C, Ludewig K, Serr A, et al. : Overwhelming Postsplenectomy Infection : A Prospective Multicenter Cohort Study. Clin Infect Dis 62 : 871-878, 2016.
PubMed
47) Witmer CM : How I approach managing student athletes at risk for bleeding. Pediatr Blood Cancer 66 : e27523, 2019.
 
48) 高橋幸博, 宮川義隆, 森麻希子, 他 (日本小児血液・がん学会 血小板委員会) : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019.
Medical*Online
49) 柏木浩和, 桑名正隆, 羽藤高明, 他 (厚生労働省難治性疾患政策研究事業 血液凝固異常症等に関する研究班「ITP治療の参照ガイド」作成委員会) : 成人特発性血小板減少性紫斑病治療の参照ガイド 2019年改訂版. 臨血 60 : 877-896, 2019.
 
50) Neunert C, Lim W, Crowther M, et al. : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
51) Ghanima W, Godeau B, Cines DB, et al. : How I treat immune thrombocytopenia : the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120 : 960-969, 2012.
PubMed
52) 宮川義隆, 柏木浩和, 高蓋寿朗, 他 (厚生労働科学研究費補助金 難治性疾患克服研究事業 血液凝固異常症に関する調査研究班 妊娠合併ITP診療の参照ガイド作成委員会) : 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨血 55 : 934-947, 2014.
 
53) 小児慢性特定疾病情報センター : 免疫性血小板減少性紫斑病 (小慢23). https://www.shouman.jp/disease/details/09_13_023/
 
54) 難病情報センター : 特発性血小板減少性紫斑病 (指定難病 63) http://www.nanbyou.or.jp/entry/303
 
P.15 掲載の参考文献
1) Rodeghiero F, Stasi R, Gernsheimer T, et al. : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
2) Neunert C, Lim W, Crowther M, et al. : The American Society Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
3) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
4) Shirahata A, Fujisawa K, Ishii E, et al. : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
5) Neunert CE, Buchanan GR, Imbach P, et al. : Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia : data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 121 : 4457-4462, 2013.
 
6) Giordano P, Urbano F, Lassandro G, et al. : Role of antithyroid autoimmunity as a predictive biomarker of chronic immune thrombocytopenia. Pediatr Blood Cancer 66 : e27452, 2019.
PubMed
7) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
8) Kelton JG, Vrbensky JR, Arnold DM : How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program 2018 : 561-567, 2018.
PubMed
9) Greinacher A, Pecci A, Kunishima S, et al. : Diagnosis of inherited platelet disorders on a blood smear : a tool to facilitate worldwide diagnosis of platelet disorders. J Thromb Haemost 15 : 1511-1521, 2017.
PubMed
10) 石黒精, 内山徹, 國島伸治 : 先天性血小板減少症・異常症の新しい診断・登録・検体保存体制. 日小児血がん会誌 57 : 227-234, 2020.
Medical*Online
11) Clarke RT, Van den Bruel A, Bankhead C, et al. : Clinical presentation of childhood leukaemia : a systematic review and meta-analysis. Arch Dis Child 101 : 894-901, 2016.
PubMed
12) Kelton JG, Powers PJ, Carter CJ : A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 60 : 1050-1053, 1982.
PubMed
13) Hazzan R, Mukamel M, Yacobovich J, et al. : Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 47 (5 suppl) : 657-659, 2006.
 
14) Altintas A, Ozel A, Okur N, et al. : Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis 24 : 163-168, 2007.
PubMed
15) Grace RF, Long M, Kalish LA, et al. : Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer 58 : 216-220, 2012.
PubMed
16) Higashigawa M, Yamamoto T, Yoshino A, et al. : Evaluation of Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura. Pediatr Int 53 : 701-705, 2011.
PubMed
17) Provan D, Arnold DM, Bussel JB, et al. : Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3 : 3780-3817, 2019.
PubMed
18) Grainger JD, Rees JL, Reeves M, et al. : Changing trends in the UK management of childhood ITP. Ach Dis Child 97 : 8-11, 2012.
 
19) Buchanan GR, Adix L : Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 141 : 683-688, 2002.
PubMed
20) Heitink-Polle KMJ, Uiterwaal CSPM, Porcelijn L, et al. : Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia : a randomized controlled trial. Blood 132 : 883-891, 2018.
PubMed
21) Okubo Y, Michihata N, Morisaki N, et al. : Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia. Int J Hematol 107 : 75-82, 2018.
PubMed
22) Schoettler ML, Graham D, Tao W, et al. : Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMPR). Pediatr Blood Cancer 64 : 10.1002/pbc.26303, 2017.
 
23) Klaassen RJ, Blanchette VS, Barnard D, et al. : Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura : the Kids' ITP tools. J Pediatr 150 : 510-515, 2007.
PubMed
24) Klaassen RJ, Blanchette V, Burke TA, et al. : Quality of life in childhood immune thrombocytopenia : international validation of the kid's ITP tools. Pediatr Blood Cancer 60 : 95-100, 2013.
 
25) Heitink-Polle KMJ, Haverman L, Annink KV, et al. : Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 99 : 1525-1531, 2014.
PubMed
26) Drainger JD, Young NL, Blanchette VS, et al. : Quality of life in immune thrombocytopenia following treatment. Ach Dis Child 98 : 895-897, 2013.
 
27) Kumar M, Lambert MP, Breakey V, et al. : Sports participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatr Blood Cancer 62 : 2223-2225, 2015.
PubMed
28) 三間屋純一, 白幡聡, 石井榮一, 他 : 小児特発性血小板減少性紫斑病 (ITP) のQOL調査成績. 日小児血液会誌 22 ; 385-390, 2008.
Medical*Online
29) Neunert CE, Buchanan GR, Imbach P, et al. : Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112 : 4003-4008, 2008.
PubMed
30) Iyori H, Bessho F, Ookawa H, et al. : Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol 79 : 691-695, 2000.
PubMed
31) Psaila B, Petrovic A, Page LK, et al. : Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP) : study of 40 cases. Blood 114 : 4777-4783, 2009.
PubMed
32) Alterkait A, Jamjoom R, Ratnapalan S : Head trauma and intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatr Emerg Care 31 : 454-458, 2015.
PubMed
P.24 掲載の参考文献
1) Schoettler ML, Graham D, Tao W, et al. : Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMPR). Pediatr Blood Cancer 64 : 10.1002/pbc.26303, 2017.
 
2) Provan D, Arnold DM, Bussel JB, et al. : Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3 : 3780-3817, 2019.
PubMed
3) Sartorius JA : Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study. Am J Pediatr Hematol Oncol 6 : 165-169, 1984.
PubMed
4) Buchanan GR, Holtkamp CA : Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 6 : 355-361, 1984.
PubMed
5) Blanchette VS, Luke B, Andrew M, et al. : A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123 : 989-995, 1993.
 
6) Fujisawa K, Iyori H, Ohkawa H, et al. : A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol 72 : 376-383, 2000.
PubMed
7) Dickerhoff R, von Ruecker A : The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 137 : 629-632, 2000.
PubMed
8) Duru F, Fisgin T, Yarali N, et al. : Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol 19 : 219-225, 2002.
 
9) Neunert CE, Buchanan GR, Imbach P, et al. : Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112 : 4003-4008, 2008.
PubMed
10) Rohmer B, Valla FV, Baleydier F, et al. : Newly diagnosed immune thrombocytopenic purpura in childhood : successful implementation of a limited intervention strategy in the setting of pediatric emergency care. J Pediatr 166 : 480-482, 2015.
PubMed
11) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-66, 2019.
PubMed
12) Kuhne T : Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie 37 : 36-44, 2017.
PubMed
13) Mithoowani S, Gregory-Miller K, Goy J, et al. : High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia : a systematic review and meta-analysis. Lancet Haematol 3 : e489-e496, 2016.
PubMed
14) Carcao M, Silva M, David M, et al. : IVMP+IVIG raises platelet counts faster than IVIG alone : results of a randomized, blinded trial in childhood ITP. Blood Adv 4 : 1492-1500, 2020.
PubMed
15) Grainger JD, Young NL, Blanchette VS, et al. : Quality of life in immune thrombocytopenia following treatment. Arch Dis Child 98 : 895-897, 2013.
PubMed
16) Neunert CE : Management of newly diagnosed immune thrombocytopenia : can we change outcomes? Blood Adv 1 : 2295-2301, 2017.
PubMed
17) Elalfy M, Reda M, Elghamry I, et al. : A randomized multicenter study : safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia. Transfusion 57 : 3019-3025, 2017.
 
18) Despotovic JM, Bussel JB : IVIg and FcγRIIb in kids with ITP : individualizing therapy. Blood 132 : 877-878, 2018.
 
19) Mithoowani S, Arnold DM : First-line Therapy for Immune Thrombocytopenia. Hamostaseologie 39 : 259-265, 2019.
PubMed
20) Imbach P, Wagner HP, Berchtold W, et al. : Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2 : 464-468, 1985.
PubMed
21) Ozsoylu S, Sayli TR, Ozturk G : Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 10 : 317-321, 1993.
PubMed
22) Blanchette V, Imbach P, Andrew M, et al. : Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 : 703-707, 1994.
PubMed
23) Rosthoj S, Nielsen S, Pedersen FK : Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group. Acta Paediatr 85 : 910-915, 1996.
 
24) Erduran E, Aslan Y, Gedik Y, et al. : A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr 45 : 295-300, 2003.
PubMed
25) Benesch M, Kerbl R, Lackner H, et al. : Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children : results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol 25 : 797-800, 2003.
 
26) Tarantino MD, Young G, Bertolone SJ, et al. : Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148 : 489-494, 2006.
 
27) Papagianni A, Economou M, Tragiannidis A, et al. : Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. J Pediatr Hematol Oncol 33 : 265-269, 2011.
PubMed
28) Celik M, Bulbul A, Aydogan G, et al. : Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura. J Thromb Thrombolysis 35 : 228-233, 2013.
PubMed
29) Heitink-Polle KMJ, Nijsten J, Boonacker CWB, et al. : Clinical and laboratory predictors of chronic immune thrombocytopenia in children : a systematic review and meta-analysis. Blood 124 : 3295-3307, 2014.
PubMed
30) Heitink-Polle KMJ, Uiterwaal CSPM, Porcelijn L, et al. : Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia : a randomized controlled trial. Blood 132 : 883-891, 2018.
PubMed
31) Schmidt DE, Heitink-Polle KMJ, Laarhoven AG, et al. : Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms. Blood Adv 3 : 2003-2012, 2019.
 
32) Lambert MP : Intravenous immunoglobulin use in children with ITP does not affect development of chronic disease. J Pediatr 204 : 320-323, 2019.
 
33) Qin YH, Zhou TB, Su LN, et al. : The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura : a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis 21 : 713-721, 2010.
PubMed
34) Bharath V, Eckert K, Kang M, et al. : Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis : a retrospective review at a single tertiary care center. Transfusion 55 : 2597-2605, 2015.
 
35) Joao C, Negi VS, Kazatchkine MD, et al. : Passive Serum Therapy to Immunomodulation by IVIG : A Fascinating Journey of Antibodies. J Immunol 200 : 1957-1563, 2018.
PubMed
36) Benadiba J, Robitaille N, Lambert G, et al. : Intravenous immunoglobulin-associated thrombosis : is it such a rare event? Report of a pediatric case and of the Quebec Hemovigilance System. Transfusion 55 : 571-575, 2015.
PubMed
37) Park KM, Yang EJ, Lim YT : Dural Venous Sinus Thrombosis and Pulmonary Embolism Following Immunoglobulin Treatment in Pediatric Patient With Immune Thrombocytopenic Purpura. J Pediatr Hematol Oncol 39 : e508-e511, 2017.
PubMed
38) Iroh Tam PY, Richardson M, Grewal S : Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP. Am J Hematol 83 : 323-325, 2008.
 
39) Heitink-Polle KMJ, Haverman L, Annink KV, et al. : Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 99 : 1525-1531, 2014.
PubMed
40) Lioger B, Maillot F, Ternant D, et al. : Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children : Systematic Review and Meta-analysis of Randomized Controlled Trials. J Pediatr 204 : 225-233.e8, 2019.
 
41) Beck CE, Nathan PC, Parkin PC, et al. : Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children : a systematic review and meta-analysis of randomized controlled trials. J Pediatr 147 : 521-527, 2005.
PubMed
42) Neunert C, Lim W, Crowther M, et al. : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
43) Kime C, Klima J, Rose MJ, et al. : Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children's hospitals. Pediatrics 131 : 880-885, 2013.
PubMed
44) Okubo Y, Michihata N, Morisaki N, et al. : Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia. Int J Hematol 107 : 75-82, 2018.
PubMed
45) Piel-Julian ML, Mahevas M, Germain J, et al. : Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost 16 : 1830-1842, 2018.
PubMed
46) Mayer B, Salama A : Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. Vox Sang 112 : 767-772, 2017.
 
47) Kuhne T, Buchanan GR, Zimmerman S, et al. : A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143 : 605-608, 2003.
 
48) Higashide Y, Hori T, Yoto Y, et al. : Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura. Pediatr Int 60 : 357-361, 2018.
PubMed
49) Neunert CE, Buchanan GR, Imbach P, et al. : Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia : data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 121 : 4457-4462, 2013.
 
50) Ducassou S, Gourdonneau A, Fernandes H, et al. : Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura : the French experience over the past 25 years. Br J Haematol 189 : 931-942, 2020.
PubMed
51) Kuhne T : Update on the Intercontinental Cooperative ITP Study Group (ICIS) and on the Pediatric and Adult Registry on Chronic ITP (PARC ITP). Pediatr Blood Cancer 6 (0 Suppl 1) : S15-S18, 2013.
 
52) Ferrara M, Bertocco F, Ferrara D, et al. : Chronic immune thrombocytopenic purpura in childhood : pathogenetic mechanisms and management. Hematology 17 : 363-366, 2012.
PubMed
P.32 掲載の参考文献
1) PROMACTA (eltrombopag) 米国添付文書. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207027s000lbl.pdf
 
2) Revolade (eltrombopag) 欧州添付文書. https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf
 
3) NPLATE (romiplostim) 米国添付文書. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125268s0026lbl.pdf
 
4) NPLATE (romiplostim) 欧州添付文書. https://www.ema.europa.eu/en/documents/product-information/nplate-epar-product-information_en.pdf
 
5) Bussel JB, de Miguel PG, Despotovic JM, et al. : Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT) : a randomised, multicentre, placebo-controlled study. Lancet Haematol 2 : e315-e325, 2015.
 
6) Grainger JD, Locatelli F, Chotsampancharoen T, et al. : Eltrombopag for children with chronic immune thrombocytopenia (PETIT2) : a randomised, multicentre, placebo-controlled trial. Lancet 386 : 1649-1658, 2015.
PubMed
7) Bussel JB, Buchanan GR, Nugent DJ, et al. : A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118 : 28-36, 2011.
PubMed
8) Elalfy MS, Abdelmaksoud AA, Eltonbary KY : Romiplostim in children with chronic refractory ITP : randomized placebo controlled study. Ann Hematol 90 : 1341-1344, 2011.
PubMed
9) Tarantino MD, Bussel JB, Blanchette VS, et al.. Romiplostim in children with immune thrombocytopenia : a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388 : 45-54, 2016.
PubMed
10) Bussel JB, Cheng G, Saleh MN, et al. : Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 : 2237-2247, 2007.
PubMed
11) Cheng G, Saleh MN, Marcher C, et al. : Eltrombopag for management of chronic immune thrombocytopenia (RAISE) : a 6-month, randomised, phase 3 study. Lancet 377 : 393-402, 2011.
 
12) Tomiyama Y, Miyakawa Y, Okamoto S, et al. : A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 10 : 799-806, 2012.
PubMed
13) Wong RSM, Saleh MN, Khelif A, et al. : Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag : final results of the EXTEND study. Blood 130 : 2527-2536, 2017.
PubMed
14) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
15) Wire MB, Li X, Zhang J, et al. : Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clin Pharmacol Ther 104 : 1199-1207, 2018.
 
16) グラクソ・スミスクライン株式会社社内資料, レボレート錠 (エルトロンボパグオラミン). https://www.pmda.go.jp/drugs/2010/P201000062/34027800_22200AMX00960_G100_1.pdf
 
17) Mathias SD, Li X, Eisen M, et al. : A phase 3, Randomized, Double-Blind, Pacebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents. Pediatr Blood Cancer 63 : 1232-1237, 2016.
 
18) Sarpatwari A, Bennett D, Logie JW, et al. : Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 95 : 1167-1175, 2010.
PubMed
19) Severinsen MT, Engebjerg MC, Farkas DK, et al. : Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia : a Danish population-based cohort study. Br J Haematol 152 : 360-362, 2011.
PubMed
20) Norgaard M, Severinsen MT, Lund Maegbaek M, et al. : Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia : a Danish population-based cohort study. Br J Haematol 159 : 109-111, 2012.
PubMed
21) Kuter DJ, Bussel JB, Newland A, et al. : Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia : safety and efficacy. Br J Haematol 161 : 161 : 411-423, 2013.
PubMed
22) Guo JC, Zheng Y, Chen HT, et al. : Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia : a meta-analysis. Oncotarget 9 : 7112-7125, 2017.
PubMed
23) Cuker A : Toxicities of the thrombopoietic growth factors. Semin Hematol 47 : 289-298, 2010.
PubMed
24) Ghanima W, Geyer JT, Lee CS, et al. : Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists : a single-center, long-term follow-up. Haematologica 99 : 937-944, 2014.
PubMed
25) Chugh S, Darvish-Kazem S, Lim W, et al. : Rituximab plus standard of care for treatment of primary immune thrombocytopenia : a systematic review and meta-analysis. Lancet Haematol 2 : e75-e81, 2015.
PubMed
26) Zaja F, Baccarani M, Mazza P, et al. : Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115 : 2755-2762, 2010.
PubMed
27) Arnold DM, Heddle NM, Carruthers J, et al. : A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 119 : 1356-1362, 2012.
PubMed
28) Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. : Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 121 : 1976-1981, 2013.
PubMed
29) Li Z, Mou W, Lu G, et al. : Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 93 : 91-98, 2011.
PubMed
30) Liang Y, Zhang L, Gao J, et al. : Rituximab for children with immune thrombocytopenia : a systematic review. PloS One 7 : e36698, 2012.
PubMed
31) Wang J, Wiley JM, Luddy R, et al. : Chronic immune thrombocytopenic purpura in children : assessment of rituximab treatment. J Pediatr 146 : 217-221, 2005.
PubMed
32) Bennett CM, Rogers ZR, Kinnamon DD, et al. : Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 : 2639-2642, 2006.
PubMed
33) Parodi E, Nobili B, Perrotta S, et al. : Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura : efficacy and safety of treatment. Int J Hematol 84 : 48-53, 2006.
PubMed
34) Matsubara K, Takahashi Y, Hayakawa A, et al. : Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 99 : 429-436, 2014.
PubMed
35) Hasan A, Michel M, Patel V, et al. : Repeated courses of rituximab in chronic ITP : Three different regimens. Am J Hematol 84 : 661-665, 2009.
PubMed
36) Provan D, Butler T, Evangelista ML, et al. : Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92 : 1695-1698, 2007.
PubMed
37) Zaja F, Vianelli N, Volpetti S, et al. : Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 85 : 329-334, 2010.
PubMed
38) Zaja F, Volpetti S, Chiozzotto M, et al. : Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 87 : 886-889, 2012.
PubMed
39) Zwaginga JJ, van der Holt B, Te Boekhorst PA, et al. : Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica 100 : e90-e92, 2015.
PubMed
40) Provan D, Stasi R, Newland AC, et al. : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
41) Pawelski S, Konopka L, Zdziechowska H : Recurrence of thrombocytopenia in patients splenectomized for idiopathic thrombocytopenic purpura. Blut 43 : 355-360, 1981.
PubMed
42) Kuhne T, Blanchette V, Buchanan GR, et al. : Splenectomy in children with idiopathic thrombocytopenic purpura : A prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 49 : 829-834, 2007.
 
43) Wang T, Xu M, Ji L, et al. : Splenectomy for chronic idiopathic thrombocytopenic purpura in children : a single center study in China. Acta Haematol 115 : 39-45, 2006.
PubMed
44) Aronis S, Platokouki H, Avgeri M, et al. : Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 93 : 638-642, 2004.
PubMed
45) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン. 日小児血液会誌 18 : 210-218, 2004.
 
46) Bhatt NS, Bhatt P, Donda K, et al. : Temporal trends of splenectomy in pediatric hospitalizations with immune thrombocytopenia. Pediatr Blood Cancer 65 : e27072, 2018.
PubMed
47) Di Sabatino A, Carsetti R, Corazza GR : Post-splenectomy and hyposplenic states. Lancet 378 : 86-97, 2011.
PubMed
48) Neunert C, Lim W, Crowther M, et al. : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
49) Chaturvedi S, Arnold DM, McCrae KR : Splenectomy for immune thrombocytopenia : down but not out. Blood 131 : 1172-1182, 2018.
 
50) Kato M, Koh K, Kikuchi A, et al. : Spontaneous improvement of chronic immune thrombocytopenia in children : experience of 56 patients at a single institute. Inter J Hematol 96 : 729-732, 2012.
 
51) Zhang J, Liang Y, Ai Y, et al. : Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia : a systematic review incorporating an indirect-comparison meta-analysis. Sci Rep 8 : 576, 2018.
PubMed
52) Zhang J, Liang Y, Ai Y, et al. : Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia : A systematic review incorporating an indirect-comparison meta-analysis. PLoS One 13 : e0198504, 2018.
 
53) Khellaf M, Viallard JF, Hamidou M, et al. : A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 98 : 881-887, 2013.
 
54) Mori M, Kato M, Koh K, et al. : Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. Rinsho Ketsueki 56 : 511-513, 2015.
 
55) Cantoni S, Carpenedo M, Mazzucconi MG, et al. : Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients : A retrospective collaborative survey from Italian hematology centers. Am J Hematol 93 : 58-64, 2018.
PubMed
56) Gonzalez-Porras JR, Godeau B, Carpenedo M : Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol 10 : 2040620719837906, 2019.
PubMed
P.37 掲載の参考文献
1) 日本小児学会 : 日本小児科学会が推奨する予防接種スケジュール. 2021 (2021年3月24日版) http://www.jpeds.or.jp/modules/activity/index.php?content_id=138
 
2) Wraith DC, Goldman M, Lambert PH : Vaccination and autoimmune disease : what is the evidence? Lancet 362 : 1659-1666, 2003.
PubMed
3) Grimaldi-Bensouda L, Michel M, Aubrun E, et al. : A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood 120 : 4938-4944, 2012.
PubMed
4) O'Leary ST, Glanz JM, McClure DL, et al. : The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 129 : 248-255, 2012.
PubMed
5) Mantadakis E, Farmaki E, Buchanan GR : Thrombocytopenic purpura after measles-mumps-rubella vaccination : a systematic review of the literature and guidance for management. J Pediatr 156 : 623-628, 2010.
PubMed
6) Kitazawa J, Nakadate H, Matsubara K, et al. : Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination : Retrospective survey of a nationwide disease registry. Int J Hematol 115 : 114-122, 2022
PubMed
7) Yokomichi H, Tanaka-Taya K, Koshida R, et al. : Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants : a matched case-control study. Int J Hematol 112 : 105-114, 2020.
PubMed
8) Morin E, Sadarangani M : Recurrent immune thrombocytopenia following different vaccines. BMJ Case Rep 12 : e231260, 2019.
PubMed
9) Gasbarrini A, Franceschi F, Tartaglione R, et al. : Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352 : 878, 1998.
PubMed
10) Cines DB, Bussel JB, Liebman HA, et al. : The ITP syndrome : pathogenic and clinical diversity. Blood 113 : 6511-6521, 2009.
PubMed
11) Takahashi T, Yujiri T, Shinohara K, et al. : Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 124 : 91-96, 2004.
PubMed
12) Stasi R, Sarpatwari A, Segal JB, et al. : Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura : a systematic review. Blood 113 : 1231-1240, 2009.
PubMed
13) Fujimura K, Kuwana M, Kurata Y, et al. : Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 81 : 162-168, 2005.
PubMed
14) 柏木浩和, 桑名正隆, 羽藤高明, 他 (厚生労働省難治性疾患政策研究事業 血液凝固異常症等に関する研究班「ITP治療の参照ガイド」作成委員会) : 成人特発性血小板減少性紫斑病治療の参照ガイド 2019 改訂版. 臨血 60 : 877-896, 2019.
 
15) 日本ヘリコバクター学会ガイドライン作成委員会 (編) : H. pylori感染の診断と治療のガイドライン. 2016 改訂版, 先端医学社, 2016.
 
16) Russo G, Miraglia V, Branciforte F, et al. : Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia : a prospective, controlled, multicenter study. Pediatr Blood Cancer 56 : 273-278, 2011.
PubMed
17) Treepongkaruna S, Sirachainan N, Kanjanapongkul S, et al. : Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura : a multi-center randomized controlled trial. Pediatr Blood Cancer 53 : 72-77, 2009.
PubMed
18) Kim BJ, Kim HS, Jang HJ, et al. : Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura : A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract 2018 : 6090878, 2018.
PubMed
19) 日本小児栄養消化器肝臓学会 : 小児期ヘリコバクター・ピロリ感染症の診療と管理ガイドライン 2018 (改訂2版). 日小児栄消肝会誌 32 : 92-136, 2018.
Medical*Online
P.40 掲載の参考文献
1) King H, Shumacker HB Jr : Splenic studies. 1. Susceptibility to infection after splenectomy performed in infancy. Ann Surg 136 : 239-242, 1952.
 
2) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
3) 高橋幸博, 宮川義隆, 森麻希子, 他 (日本小児血液・がん学会血小板委員会) : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019.
Medical*Online
4) Aronis S, Platokouki H, Avgeri M, et al. : Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 93 : 638-642, 2004.
PubMed
5) Provan D, Stasi R, Newland AC, et al. : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
6) Holdsworth RJ, Irving AD, Cuschieri A : Postsplenectomy sepsis and its mortality rate : actual versus perceived risks. Br J Surg 78 : 1031-1038, 1991.
PubMed
7) Price VE, Dutta S, Blanchette VS, et al : The prevention and treatment of bacterial infections in children with asplenia or hyposplenia : practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 46 : 597-603, 2006.
PubMed
8) Stryker RM, Orton DW : Overwhelming postsplenectomy infection. Ann Emerg Med 17 : 161-164, 1988.
PubMed
9) Di Cataldo A, Puleo S, Li Destri G, et al. : Splenic trauma and overwhelming postsplenectomy infection. Br J Surg 74 : 343-345, 1987.
PubMed
10) Mantadakis E, Buchanan GR : Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 22 : 148-153, 2000.
PubMed
11) Khasawneh MA, Contreras-Peraza N, Hernandez MC, et al. : Outcomes after splenectomy in children : a 48-year population-based study. Pediatr Surg Int 35 : 575-582, 2019.
PubMed
12) Kuhn T, Blanchette V, Buchanan GR, et al. : Splenectomy in children with idiopathic thrombocytopenic purpura : A prospective study of 134 children from the intercontinental childhood ITP study group. Pediatr Blood Cancer 49 : 829-834, 2007.
 
13) Gwilliam NR, Lazar DA, Brandt ML, et al. : An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. J Pediatr Surg 47 : 1537-1541, 2012.
 
14) Sinwar PD : Overwhelming post splenectomy infection syndrome- review study. Int J Surg 12 : 1314-1316, 2014.
PubMed
15) 「小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014」作成委員会 (作成), 日本小児感染症学会 (監) : 無脾症および脾摘患者への予防接種. 小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014. 協和企画, 112-118, 2014.
 
16) Davidson RN, Wall RA : Prevention and management of infection in patients without a spleen. Clin Microbiol Infect 7 : 657-660, 2001.
PubMed
17) Jugenburg M, Haddock G, Freedman MH, et al. : The morbidity and mortality of pediatric splenectomy : does prophylaxis make a difference? J Pediatr Surg 34 : 1064-1067, 1999.
PubMed
18) Harji DP, Jaunoo SS, Mistry P, et al. : Immunoprophylaxis in asplenic patients. Int J Surg 7 : 421-423, 2009.
PubMed
19) Rubin LG, Schaffner W : Care of the asplenic patient. N Engl J Med 371 : 349-356, 2014.
 
20) 日本小児科学会 予防接種・感染症対策委員会 : 任意接種ワクチンの小児 (15 歳未満) への接種. 2021年5月改訂. http://www.jpeds.or.jp/uploads/files/nini_vaccine202105.pdf
 
21) 渡辺彰, 大石和徳, 大島信治, 他 (日本感染症学会 肺炎球菌ワクチン再接種問題検討委員会) : 肺炎球菌ワクチン再接種のガイダンス (改訂版). 感染症誌 91 : 543-552, 2017. http://www.kansensho.or.jp/uploads/files/guidelines/pneumococcus_vaccine_re_1707.pdf
 
22) 日本小児科学会 予防接種・感染症対策委員会 : 定期接種対象外の年齢小児 (15歳未満) へのワクチン接種. 2020年12月改訂. http://www.jpeds.or.jp/uploads/files/teikigai_%20vaccine202012.pdf
 
23) 堀越泰雄 : 小児血液疾患における脾臓摘出術の適応と役割. 日小児血液会誌 17 : 461-472, 2003.
 
24) 橋本直樹 : 脾摘後重症感染症の予防と対策. 日門亢会誌 20 : 16-18, 2014.
 
25) 国立感染症研究所 : 髄膜炎菌性髄膜炎とは. 2015年5月更新. http://www.niid.go.jp/niid/ja/kansennohanashi/405-neiseria-meningitis.html
 
26) 藤沢康司 : 小児ITPに対する治療ガイドラインの現況とその検証. 臨血 45 : 428-435, 2004.
 
27) Gaston MH, Verter JI, Woods G, et al. : Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314 : 1593-1599, 1986.
 
28) 江原英治, 村上洋介, 佐々木赳, 他 : 無脾症候群における重症細菌感染症 (髄膜炎・敗血症) の検討 : 早期診断の重要性とワクチン予防に関する考察. 日小児循環器会誌 30 ; 39-46, 2014.
 
29) Kaplinsky C, Spirer Z : Post-splenectomy antibiotic prophylaxis-unfinished story : to treat or not to treat? Pediatr Blood Cancer 47 (5 Suppl) : 740-741, 2006.
PubMed
P.44 掲載の参考文献
1) 「小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014」作成委員会 (作成), 日本小児感染症学会 (監) : 小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014. 協和企画, 2014.
 
2) Kroger AT, Atkinson WL, Marcuse EK, et al. : General recommendation on immunization : recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 : 1-48, 2006.
PubMed
3) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
4) Immunization in special circumstances. In : Pickering LK, Baker CJ, Kimberlin DW, et al. (eds) : Red Book : 2012 Report of the committee on infectious diseases. 29th ed, American Academy of Pediatrics, Elk Grove Village, IL, 69-109, 2012.
 
5) Dowell SF, Bressee JS : Severe varicella associated with steroid use. Pediatrics 92 : 223-228, 1993.
 
6) 高橋幸博, 宮川義隆, 森麻希子, 他 (日本小児血液・がん学会血小板委員会) : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019.
Medical*Online
7) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
8) Kelton JG, Vrbensky JR, Arnold DM : How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program 2018 : 561-567, 2018.
PubMed
9) Matsubara K, Takahashi Y, Hayakawa A, et al. : Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 99 : 429-436, 2014.
PubMed
10) Malpica L, van Duin D, Moll S : Preventing infection complications when treating non-malignant immune-mediated hematologic disorders. Am J Hematol 94 : 1396-1412, 2019.
PubMed
11) Nazi I, Kelton JG, Larche M, et al. : The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122 : 1946-1953, 2013.
PubMed
P.47 掲載の参考文献
1) Gernsheimer T, James AH, Stasi R : How I treat thrombocytopenia in pregnancy. Blood 121 : 38-47, 2013.
 
2) Gill KK, Kelton JG : Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol 37 : 257-289, 2000.
 
3) Care A, Pavord S, Knight M, et al. : Severe primary autoimmune thrombocytopenia in pregnancy : a national cohort study. BJOG 125 : 604-612, 2018.
PubMed
4) Fujimura K, Harada Y, Fujimoto T, et al. : Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol 75 : 426-433, 2002.
PubMed
5) Koyama S, Tomimatsu T, Kanagawa T, et al. : Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. Am J Hematol 87 : 15-21, 2012.
PubMed
6) Kelton JG : Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 16 : 43-46, 2002.
PubMed
7) Yamada H, Kato EH, Kishida T, et al. : Risk factors for neonatal thrombocytopenia in pregnancy complicated by idiopathic thrombocytopenic purpura. Ann Hematol 76 : 211-214, 1998.
PubMed
8) Provan D, Stasi R, Newland AC, et al. : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
9) Kawaguchi K, Matsubara K, Takafuta T, et al. : Factors predictive of neonatal thrombocytopenia in pregnant women with immune thrombocytopenia. Int J Hematol 99 : 570-576, 2014.
PubMed
10) van der Lugt NM, van Kampen A, Walther FJ, et al. : Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang 105 : 236-243, 2013.
PubMed
11) 小林道弘, 小山麻里, 杉山謙二, 他 : 超大量免疫グロブリンの投与を試みた新生児passive immune thrombocytopeniaの治療経験. 日産婦新生児血会誌 1 : 94-95, 1991.
 
12) 藤沢康司 : 小児ITPに対する治療ガイドラインの現況とその検証. 臨血 45 : 428-435, 2004.
 
13) 伊従秀章, 赤塚純一 : ITPにおける妊娠・分娩の管理. 血腫瘍 32 : 452-460, 1996.
 
14) Kunishima S, Saito H : Congenital macrothrombocytopenias. Blood Rev 20 : 111-121, 2006.
PubMed
15) 笹原洋二 : ITPと鑑別が必要な小型・正常大の血小板を有する遺伝性血小板減少症. 日小児血がん会誌 52 : 311-316, 2015.
Medical*Online
16) Kadir RA, McLintock C : Thrombocytopenia and disorders of platelet function in pregnancy. Semin Thromb Hemost 37 : 640-652, 2011.
PubMed
17) 宮川義隆, 柏木浩和, 高蓋寿朗, 他 (厚生労働科学研究費補助金 難治性疾患克服研究事業 血液凝固異常症に関する調査研究班 妊娠合併ITP診療の参照ガイド作成委員会) : 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨血 55 : 934-947, 2014.
 
18) Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev 22 : 173-186, 2008.
PubMed
19) 厚生労働省・生活衛生局 : IV 血小板濃厚液の適正使用, VII 新生児・小児に対する輸血療法. 血液製剤の使用指針. 2018. https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000203007.pdf
 
P.50 掲載の参考文献
1) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
2) 高橋幸博, 宮川義隆, 森麻希子, 他 (日本小児血液・がん学会血小板委員会) : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019.
Medical*Online
3) Bussel JB, Goldman A, Imbach P, et al. : Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediatr 106 : 886-890, 1985.
PubMed
4) Blanchette VS, Luke B, Andrew M, et al. : A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123 : 989-995, 1993.
 
5) Blanchette V, Imbach P, Andrew M, et al. : Randomized trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 : 703-707, 1994.
PubMed
6) Shirahata A, Ishii E, Eguchi H, et al. : Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura. Int J Hematol 83 : 29-38, 2006.
PubMed
7) Shirahata A, Fujisawa K, Ishii E, et al. : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
8) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
9) Higashigawa M, Yamamoto T, Yoshino A, et al. : Evaluation of Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura. Pediatr Int 53 : 701-705, 2011.
PubMed
10) Fujisawa K, Iyori H, Ohkawa H, et al. : A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol 72 : 376-383, 2000.
PubMed
11) Psaila B, Petrovic A, Page LK, et al. : Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP) : Study of 40 cases. Blood 114 : 4777-4783, 2009.
PubMed
12) Neunert CE, Buchanan GR, Imbach P, et al. : Severe hemorrhage in children with newly diagnosed immune thrombocytopenia. Blood 112 : 4003-4008, 2008.
PubMed
13) Neunert C, Noroozi N, Norman G, et al. : Severe bleeding events in adults and children with primary immune thrombocytopenia : a systematic review. J Thromb Haemost 13 : 457-464, 2015.
PubMed
14) Alterkait A, Jamjoom R, Ratnapalan S : Head trauma and intracranial hemorrhage in children with immune thrombocytopenic purpura. Pediatr Emerg Care 31 : 454-458, 2015.
PubMed
15) Choudhary DR, Naithani R, Mahapatra M, et al. : Intracranial hemorrhage in childhood immune thrombocytopenic purpura. Pediatr Blood Cancer 52 : 529-531, 2009.
PubMed
16) Arnold DM : Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2015 : 237-242, 2015.
PubMed
17) Butros LJ, Bussel JB : Intracranial hemorrhage in immune thrombocytopenic purpura : a retrospective analysis. J Pediatr Hematol Oncol 25 : 660-664, 2003.
PubMed
18) Iyori H, Bessho F, Ookawa H, et al. (Japanese Study Group of Childhood ITP) : Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol 79 : 691-695, 2000.
 
19) Bavunoglu I, Eskazan AE, Ar MC, et al. : Treatment of patients with immune thrombocytopenia admitted to the emergency room. Int J Hematol 104 : 216-222, 2016.
 
20) Youssef MAM, Eldeen ES, Elsayh KI, et al. : High dose dexamethasone as an alternative rescue therapy for active bleeding in children with chronic ITP : clinical and immunological effects. Platelets 30 : 886-892, 2019.
 
21) Liu Z, Wang M, Zhou S, et al. : Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia. J Transl Med 14 : 301, 2016.
 
22) Carcao M, Silva M, David M, et al. : IVMP+IVIG raises platelet counts faster than IVIG alone : results of a randomized, blind trial in childhood ITP. Blood Adv 4 : 1492-1500, 2020.
PubMed
23) Neunert CE, Rose MJ : Romiplostim for the management of pediatric immune thrombocytopenia : drug development and current practice. Blood Adv 3 : 1907-1915, 2019.
PubMed
24) Gellens R, Habchi S, Freppel S, et al. : Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage. Front Neurol 8 : 737, 2018.
PubMed
P.55 掲載の参考文献
1) Neunert C, Terrell DR, Arnold DM, et al. : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
2) Bennett CM, Neunert C, Grace RF, et al. : Predictors of remission in children with newly diagnosed immune thrombocytopenia : Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 65 : doi : 10.1002/pbc.26736, 2018.
 
3) Imbach P, Kuhne T, Muller D, et al. : Childhood ITP : 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 46 : 351-356, 2006.
 
4) Lassandro G, Palmieri VV, Palladino V, et al. : Sport and Children with Immune Thrombocytopenia : Never Give Up. Curr Sports Med Rep 18 : 317-318, 2019.
PubMed
5) Kuhne T, Imbach P, Bolton-Maggs PH, et al. : Newly diagnosed idiopathic thrombocytopenic purpura in childhood : an observational study. Lancet 358 : 2122-2125, 2001.
PubMed
6) Stasi R, Evangelista ML, Stipa E, et al. : Idiopathic thrombocytopenic purpura : current concepts in pathophysiology and management. Thromb Haemost 99 : 4-13, 2008.
PubMed
7) Provan D, Stasi R, Newland AC, et al. : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
8) D'Orazio JA, Neely J, Farhoudi N : ITP in children : pathophysiology and current treatment approaches. J Pediatr Hematol Oncol 35 : 1-13, 2013.
PubMed
9) Psaila B, Petrovic A, Page LK, et al. : Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP) : study of 40 cases. Blood 114 : 4777-4783, 2009.
PubMed
10) Kumar M, Lambert MP, Breakey V, et al. : Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatr Blood Cancer 62 : 2223-2225, 2015.
PubMed
11) Daneshvar DH, Nowinski CJ, McKee AC, et al. : The epidemiology of sport-related concussion. Clin Sports Med 30 : 1-17, 2011.
PubMed
12) Lincoln AE, Caswell SV, Almquist JL, et al. : Trends in concussion incidence in high school sports : a prospective 11-year study. Am J Sports Med 39 : 958-963, 2011.
PubMed
13) Howell C, Scott K, Patel DR : Sports participation recommendations for patients with bleeding disorders. Transl Pediatr 6 : 174-180, 2017.
PubMed
14) De Mattia D, Del Vecchio GC, Russo G, et al. : Management of chronic childhood immune thrombocytopenic purpura : AIEOP consensus guidelines. Acta Haematol 123 : 96-109, 2010.
PubMed
15) Provan D, Arnold DM, Bussel JB, et al. : Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3 : 3780-3817, 2019.
PubMed
16) Blair SN, LaMonte MJ, Nichaman MZ : The evolution of physical activity recommendations : how much is enough? Am J Clin Nutr 79 : 913S-920S, 2004.
PubMed
17) World Health Organization : 4.2 Age group : 5-17 years old. Global recommendations on physical activity for health. WHO, 2010.
 
18) Wang W, Bourgeois T, Klima J, et al. : Iron deficiency and fatigue in adolescent females with heavy menstrual bleeding. Haemophilia 19 : 225-230, 2013.
 
19) Kuter DJ, Mathias SD, Rummel M, et al. : Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 87 : 558-561, 2012.
 
20) Trotter P, Hill QA : Immune thrombocytopenia : improving quality of life and patient outcomes. Patient Relat Outcome Meas 9 : 369-384, 2018.
PubMed
21) Jarzabek-Bielecka G, Mizgier M, Kedzia W : Metrorrhagia iuvenilis and Premenstrual Syndrome as frequent problems of adolescent gynecology with aspects of diet therapy. Ginekol Pol 90 : 423-429, 2019.
PubMed
22) Levens ED, Scheinberg P, DeCherney AH : Severe menorrhagia associated with thrombocytopenia. Obstet Gynecol 110 : 913-917, 2007.
PubMed
23) O'Brien B, Mason J, Kimble R : Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding : The Queensland Statewide Paediatric and Adolescent Gynaecology Service. J Pediatr Adolesc Gynecol 32 : 122-127, 2019.
 
24) Alaqzam TS, Stanley AC, Simpson PM, et al. : Treatment Modalities in Adolescents who Present with Heavy Menstrual Bleeding. J Pediatr Adolesc Gynecol 31 : 451-458, 2018.
PubMed
25) Powers JM, Stanek JR, Srivaths L, et al. : Hematologic Considerations and Management of Adolescent Girls with Heavy Menstrual Bleeding and Anemia in US Children's Hospitals. J Pediatr Adolesc Gynecol 31 : 446-450, 2018.
PubMed
26) Haamid F, Sass AE, Dietrich JE : Heavy Menstrual Bleeding in Adolescents. J Pediatr Adolesc Gynecol 30 : 335-340, 2017.
PubMed
P.60 掲載の参考文献
1) 高橋幸博, 宮川義隆, 森麻希子, 他 (日本小児血液・がん学会血小板委員会) : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019.
Medical*Online
1) Schreiber AD, Chien P, Tomaski A, et al. : Effect of danazol in immune thrombocytopenic purpura. N Engl J Med 316 : 503-508, 1987.
PubMed
1) Bergan S : Optimization of azathioprine immunosuppression after organ transplantation by pharmacological measurements. BioDrugs 8 : 446-456, 1997.
 
1) Verlin M, Laros RK Jr, Penner JA : Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1 : 97-104, 1976.
PubMed
1) Kappers-Klunne MC, van't Veer MB : Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 114 : 121-125, 2001.
PubMed
1) Taylor A, Neave L, Solanki S, et al. : Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol 171 : 625-630, 2015.
PubMed
1) Moss C, Hamilton PJ : Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. BMJ 297 : 266, 1988.
PubMed
1) Nomura T, Maekawa T, Uchino H, et al. : Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura ; a multicenter cooperative study. Nihon Ketsueki Gakkai Zasshi 53 : 98-104, 1990.
PubMed
2) Arnold DM, Nazi I, Santos A, et al. : Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 115 : 29-31, 2010.
PubMed
2) Durand JM, Lefevre P, Hovette P, et al. : Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection. Am J Med 90 : 675-677, 1991.
PubMed
2) Hou M, Peng J, Shi Y, et al. : Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 70 : 353-357, 2003.
PubMed
2) Reiner A, Gernsheimer T, Slichter SJ : Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 85 : 351-358, 1995.
PubMed
2) Manoharan A : Targeted-immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia. Aust N Z J Med 21 : 405-407, 1991.
PubMed
2) 柏木浩和, 桑名正隆, 羽藤高明, 他 (厚生労働省難治性疾患政策研究事業 血液凝固異常症等に関する研究班「ITP治療の参照ガイド」作成委員会) : 成人特発性血小板減少性紫斑病治療の参照ガイド 2019 改訂版. 臨血 60 : 877-896, 2019.
 
2) Wang S, Yang R, Zou P, et al. : A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol 96 : 222-228, 2012.
 
2) Quiquandon I, Fenaux P, Caulier MT, et al. : Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura : a report on 53 cases. Br J Haematol 74 : 223-228, 1990.
PubMed
3) Choi PY, Roncolato F, Badoux X, et al. : A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 126 : 500-503, 2015.
PubMed
3) Durand JM, Lefevre P, Hovette P, et al. : Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol 78 : 459-460, 1991.
PubMed
3) Kotlarek-Haus S, Podolak-Dawidziak M : Danazol in chronic idiopathic thrombocytopenic purpura resistant to corticosteroids. Folia Haematol Int Mag Klin Morphol Blutforsch 114 : 768-776, 1987.
PubMed
3) Zhang WG, Ji L, Cao XM, et al. : Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 26 : 598-602, 2005.
PubMed
3) Schwartz R, Dameshek W : The treatment of autoimmune hemolytic anemia with 6-mercaptopurine and thioguanine. Blood 19 : 483-500, 1962.
 
3) Fenaux P, Quiquandon I, Caulier MT, et al. : Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura : a report on 43 cases. Blut 60 : 238-241, 1990.
PubMed
3) Cuker A, Neunert CE : How I treat refractory immune thrombocytopenia. Blood 128 : 1547-1554, 2016.
 
3) Neunert C, Terrell DR, Amold DM, et al : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
 
4) Choudhary DR, Naithani R, Mahapatra M, et al. : Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 93 : e61-e62, discussion e63, 2008.
PubMed
4) Proven D, Moss AJ, Newland AC, et al. : Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 81 : 19-25, 2006.
 
4) Cuker A, Neunert CE : How I treat refractory immune thrombocytopenia. Blood 128 : 1547-1554, 2016.
 
4) Rice L : Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. Am J Med 117 : 972-973, 2004.
PubMed
4) Joseph A, Evans DI : Immunosuppressive treatment of idiopathic thrombocytopenic purpura in children. Acta Paediatr Scand 71 : 467-469. 1982.
 
4) Durand JM, Lefevre P, Kaplanski G et al. : Correction of thrombocytopenia with dapsone in primary antiphospolipid syndrome. J Rheumatol 20 : 1777-1778, 1993.
 
4) Poudyal BS, Sapkota B, Shrestha GS, et al. : Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura. J Nepal Med Assoc 55 : 16-21, 2016.
PubMed
5) Perrotta S, Amendola G, Locatelli F, et al. : Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 121 : 143-147, 2003.
PubMed
5) Park YH, Sunamoto M, Miyoshi T, et al. : Effectiveness of dapsone on refractory immune thrombocytopenia in a patient with systemic lupus erythematosus associated with sarcoidosis. Rinsho Ketsueki 34 : 870-875, 1993.
 
5) Rocha R, Horstman L, Ahn YS, et al. : Danazol therapy for cyclic thrombocytopenia. Am J Hematol 36 : 140-143,1991.
PubMed
5) Depre F, Aboud N, Mayer B, et al. : Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia : Results from a long-term observation in clinical practice. PLoS One 13 : e0198184, 2018.
PubMed
5) Massimo L, Genova R, Marchi A, et al. : More on vincristine in treatment of ITP in children. N Engl J Med 297 : 397-398, 1977.
PubMed
5) Colovic M, Suvajdzic N, Colovic N, et al. : Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets 22 : 153-156, 2011.
 
6) Ahn YS, Harrington WJ, Mylvaganam R, et al. : Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura Ann Intern Med 100 : 192-196, 1984.
PubMed
6) Miano M, Ramenghi U, Russo G, et al. : Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol 175 : 490-495, 2016.
 
6) Liu AP, Cheuk DK, Lee AH, et al. : Cyclosporin A for persistent or chronic immune thrombocytopenia in children. Ann Hematol 95 : 1881-1886, 2016.
PubMed
6) Zuidema J, Hilbers-Modderman ES, Merkus FW : Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11 : 299-315, 1986.
PubMed
6) Ahn YS, Harrington WJ, Mylvaganam R, et al. : Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 102 : 298-301, 1985.
PubMed
6) Sobota A, Neufeld EJ, Lapsia S, et al. : Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer 52 : 80-84, 2009.
PubMed
7) Godeau B, Oksenhendler E, Bierling P : Dapsone for autoimmune thrombocytopenic purpura. Am J Hematol 44 : 70-72, 1993.
PubMed
7) Cuker A, Neunert CE : How I treat refractory immune-thrombocytopenia. Blood 128 : 1547-1554, 2016.
 
7) Howard J, Hoffbrand AV, Prentice HG, et al. : Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 117 : 712-715, 2002.
PubMed
7) Buelli M, Cortelazzo S, Viero P, et al. : Danazol for the treatment of idiopathic thrombocytopenic purpura. Acta Haematol 74 : 97-98, 1985.
PubMed
7) Sussman LN : Azathioprine in refractory idiopathic thrombocytopenic purpura. JAMA 202 : 259-263, 1967.
PubMed
7) Facon T, Caulier MT, Wattel E, et al. : A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura : a report on 42 patients. Br J Haematol 86 : 678-680, 1994.
 
8) Linares M, Cervero A, Pastor E, et al. : Dapsone for idiopathic thrombocytopenic purpura. Am J Hematol 46 : 371-372, 1994.
PubMed
8) Stirnemann J, Kaddouri N, Khellaf M, et al. : Vincristine efficacy and safety in treating immune thrombocytopenia : a retrospective study of 35 patients. Eur J Haematol 96 : 269-275, 2016.
PubMed
8) Chang H, Tang TC, Hung YS, et al. : Immune thrombocytopenia : Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol 101 : 549-555, 2018.
PubMed
8) Aslanis V, Zhang J, Lomeli B, et al. : Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteer. Cancer Chemother Pharmacol 82 : 847-855, 2018.
PubMed
8) Kotb R, Pinganaud C, Trichet C, et al. : Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias : a single center preliminary study. Eur J Haematol 75 : 60-64, 2005.
PubMed
8) Almagro D : Danazol in idiopathic thrombocytopenic purpura. Acta Hematol (Basel) 74 : 120, 1985.
 
9) Park YH, Yi HG, Lee MH, et al. : Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia : a retrospective single-center study. Int J Hematol 103 : 180-188, 2016.
PubMed
9) Hernandez F, Linares M, Colomina P, et al. : Dapsone for refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 90 : 473-475, 1995.
PubMed
9) Hilgartner MW, Lanzkowsky P, Smith CH : The use of azathioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Paediatr Scand 59 : 409-415, 1970.
PubMed
9) McVerry BA, Auger M, Bellingham AJ : The use of danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol 61 : 145-148, 1985.
PubMed
10) Marinaki AM, Ansari A, Duley JA, et al. : Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophospatase (ITPase). Pharmacogenetics 14 : 181-187, 2004.
 
10) Godeau B, Durand JM, Roudot-Thoraval F, et al. : Dapsone for chronic autoimmune thrombocytopenic purpura : a report of 66 cases. Br J Haematol 97 : 336-339, 1997.
PubMed
10) Heyd J, Hershko C : Use of danazol in the management of chronic idiopathic thrombocytopenic purpura. Isr J Med Sci 21 : 418-420, 1985.
PubMed
11) Yang SK, Hong M, Baek J et al. : A common missense variant in NUDT15 confers susceptibility in thiopurine-induced leukopenia. Nat Genet 46 : 1017-1020, 2014.
 
11) Ambriz R, Pizzuto J, Morales M, et al. : Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouv Rev Fr Hematol 28 : 275-279, 1986.
PubMed
11) Radaelli F, Calori R, Goldaniga M, et al. : Adult refractory chronic idiopathic thrombocytopenic purpura : can dapsone be proposed as secondline therapy? Br J Haematol 104 : 641-642, 1999.
PubMed
12) Hirasawa A, Sato T, Kawabuchi Y et al. : Diaminodiphenyl sulfone therapy for refractory idiopathic thrombocytopenic purpura--long-term effectiveness and possible mechanisms. Rinsho Ketsueki 40 : 1068-1073, 1999.
PubMed
12) Ahn YS, Fernandez LF, Kim CI, et al. : Danazol therapy renders red cells resistant to osmotic lysis. FASEB J 3 : 157-162, 1989.
PubMed
12) Tanaka Y, Kato M, Hasegawa D, et al. : Susceptibility to 6-MP toxicity conferred by a NUDT 15 variant in Japanese children with acute lymphoblastic leukemia. Br J Haematol 171 : 105-115, 2015.
 
13) Vancine-Califani SM, De Paula EV, Ozelo MC et al. : Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets 19 : 489-495, 2008.
 
13) Moriyama T, Nishii R, Perez-Andreu V, et al. : NUDT15 polymorphisms after thiopurine metabolism and hematopoietic toxicity. Nat Genet 48 : 367-373, 2016.
 
13) Edelmann DZ, Knobel B, Virag I et al. : Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura. Postgrad Med J 66 : 827-830, 1990.
PubMed
14) Sundar S, Moorleedursingh GS, Kumar K, et al. : Danazol therapy in chronic idiopathic thrombocytopenic purpura. J Assoc Physicians India 40 : 350-351, 1992.
PubMed
14) Tsujimoto S, Osumi T, Uchiyama M, et al. : Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms. Lekemia 32 : 2710-2714, 2018.
 
14) Rodrigo C, Gooneratne L : Dapsone for primary immune thrombocytopenia in adults and children : an evidence-based review. J Thromb Haemost 11 : 1946-1953, 2013.
PubMed
15) Schiavotto C, Castaman G, Rodeghiero F : Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica 78 (6 Suppl 2) : 29-34, 1993.
 
15) Lee JY, Lee JO, Jung JY, et al. : Dapsone therapy for refractory immune thrombocytopenia patients : a case series. Blood Res 52 : 95-99, 2017.
PubMed
15) Kakuta Y, Kawai Y, Okamoto D, et al. : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events of Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 53, 1065-1078, 2018.
PubMed
16) Cuker A, Neunert CE : How I treat refractory immune-thrombocytopenia. Blood 128 : 1547-1554, 2016.
 
16) Esteve C, Samson M, Guilhem A, et al. : Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia : A retrospective study of 42 patients. PLoS One 12 : e0187296, 2017.
PubMed
17) Damodar S, Viswabandya A, George B, et al. : Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients. Eur J Haematol 75 : 328-331, 2005.
PubMed
17) Fenaux P, Quiquandon I, Huart JJ, et al. : The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases. Nouv Rev Fr Hematol 32 : 143-146, 1990.
PubMed
18) Ruberto E, Espinola R : Treatment of idiopathic thrombocytopenic purpura with danazol. Sangre (Barc) 40 : 307-310, 1995.
PubMed
18) Patel AP, Patil AS : Dapsone for immune thrombocytopenic purpura in children and adults. Platelets 26 : 164-167, 2015.
PubMed
19) Le Louet H, Ruivart M, Bierling P et al. : Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura. Am J Hematol 62 : 251-252, 1999.
PubMed
19) Li HQ, Zhang L, Zhao H, et al. : Chronic idiopathic thrombocytopenic purpura in adult Chinese patients : a retrospective single-centered analysis of 1791 cases. Chin Med J (Engl) 118 : 34-37, 2005.
 
20) Dutta TK, Goel A, Ghotekar LH, et al. : Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults. J Assoc Physicians India 49 : 421-425, 2001.
PubMed
20) Liu W, Gu X, Fu R, et al. : The Effect of Danazol in Primary Immune Thrombocytopenia : An Analysis of a Large Cohort From a Single Center in China. Clin Appl Thromb Hemost 22 : 727-733, 2016.
PubMed
21) Weber E, Reynaud Q, Fort R, et al. : Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura : A PRISMAcompliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore) 96 : e7534, 2017.
PubMed
21) Meeker ND, Goldsby R, Terrill KR, et al. : Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol 25 : 173-175, 2003.
PubMed
22) Audia S, Lakomy D, Guy J, et al. : Treatment of immune thrombocytopenia ; a retrospective study of 40 patients. Rev Med Interne 31 : 337-344, 2010.
PubMed
23) Zaja F, Marin L, Chiozzotto M, et al. : Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol 87 : 321-323, 2012.
PubMed
24) Khan YB, Ahmed A, Geelani SS, et al. : Dapson as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries : A prospective cohort study. J Appl Hematol 5 : 86-90, 2014.
 
25) Kundu R, Sethi N, Ghose A, et al. : Age old dapsone in the treatment of idiopathic thrombocytopenic purpura--a case report with review. Am J Ther 20 : e723-e725, 2013.
PubMed
26) Schiff DE, Roberts WD, Sue YJ : Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. J Pediat Hematol Oncol 28 : 395-398, 2006.
 

付録 小児難治性ITP治療ガイド2019

P.85 掲載の参考文献
1) 白幡聡, 石井榮一, 江口春彦, 他 (日本小児血液学会ITP委員会) : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
2) British Committee for Standards in Haematology General Haematology Task Force : Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 : 574-596, 2003.
PubMed
3) Neunert C, Lim W, Crowther M, et al : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
4) Iyori H, Bessho F, Ookawa H, et al. (Japanese Study Group on childhood ITP) : Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol 79 : 691-695, 2000.
 
5) Lilleyman JS : Intracranial hemorrhage in idiopathic thrombocytopenic purpura. Pediatric Haematology Forum of the British Society of Haematology. Arch Dis Child 71 : 251-253, 1994.
PubMed
6) Guyatt GH, Cook DJ, Jaeschke R, et al. : Grades of recommendation for antithrombotic agents : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 Suppl) : 123S-131S, 2008.
 
7) Bengtson KL, Skinner MA, Ware RE : Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 143 : 670-673, 2003.
PubMed
8) Pusiol A, Cesaro S, Nocerino A, et al. : Successful treatment with monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 163 : 305-307, 2004.
PubMed
9) Trelinski J, Chojnowski K, Kurenko-Deptuch M, et al. : Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporine A in a patient with chronic granulomatous disease. Ann Hematol 84 : 835-836, 2005.
 
10) Taube T, Schmid H, Reinhard H, et al. : Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in children. Haematologica 90 : 281-283, 2005.
PubMed
11) Wang J, Wiley JM, Luddy R, et al. : Chronic immune thrombocytopenic purpura in children : assessment of rituximab treatment. J Pediatr 146 : 217-221, 2005.
PubMed
12) Bennett CM, Rogers ZR, Kinnamon DD, et al. : Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 : 2639-2642, 2006.
PubMed
13) Parodi E, Nobili B, Perrotta S, et al. : Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura : efficacy and safety of treatment. Int J Hematol 84 : 48-53, 2006.
PubMed
14) Mahevas M, Le Page L Salle V, et al. : Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency. Am J Hematol 81 : 645-646, 2006.
PubMed
15) Bay A, Oner AF, Uner A, et al. : Use of rituximab in chronic childhood immune thrombocytopenic purpura. Pediatr Int 48 : 514-516, 2006.
PubMed
16) Franchini M, Zaffanello M, Veneri D, et al. : Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors. Pediatr Blood Cancer 49 : 6-10, 2007.
PubMed
17) Parodi E, Rivetti E, Amendola G, et al. : Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP : identification of factors predictive of a sustained response. Br J Haematol 144 : 552-558, 2009.
PubMed
18) Dogan M, Oner AF, Acikqoz M, et al. : Treatment of chronic immune thrombocytopenic purpura with rituximab in children. Indian J Pediatr 76 : 1141-1144, 2009.
 
19) Mueller BU, Bennett CM, Feldman HA, et al. : One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer 52 : 259-262, 2009.
PubMed
20) Goto S, Goto H, Tanoshima R, et al. : Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 89 : 305-309, 2009.
 
21) Iesato K, Hatakeyama N, Yamamoto M, et al. : Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab. Pediatr Blood Cancer 53 : 203-205, 2009.
PubMed
22) Polido-Pereira J, Ferreira D, Rodrigues AM, et al. : Rituximab use in pediatric autoimmune diseases : four case reports. Ann N Y Acad Sci 1173 : 712-720, 2009.
PubMed
23) 柴田真弓, 今村俊彦, 吉田路子, 他 : 難治性慢性血小板減少に対しrituximab投与を行った3例. 第51回日本小児血液学会, 305, 2009.
 
24) Citak EC, Citak FE : Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. J Trop Pediatr 57 : 71-72, 2011.
PubMed
25) Stiakaki E, Prdikogianni C, Thomou C, et al. : Idiopathic thrombocytopenic purpura in childhood : twenty years of experience in a single center. Pediatr Int 54 : 524-527, 2012.
 
26) Patel VL, Mahevas M, Lee SY, et al. : Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 119 : 5989-5995, 2012.
PubMed
27) Gokcebay DG, Tavil B, Fettah A, et al. : Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab. Clin Appl Thromb Hemost 19 : 663-667, 2013.
 
28) 大内芽里, 星能元, 佐藤篤, 他 : リツキシマブが奏功した臍帯移植後免疫性血小板減少症の1例. 日小児会誌 115 : 691, 2011.
 
29) Ansari Sh, Rostami T, Yousefian S, et al. : Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura. Pediatr Hematol Oncol 31 : 555-562, 2014.
PubMed
30) Matsubara K, Takahashi Y, Hayakawa A, et al. : Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 99 : 429-436, 2014.
PubMed
31) Ay Y, Karapinar TH, Oymak Y, et al. : Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Blood Coagul Fibrinolysis 27 : 431-435, 2016.
PubMed
32) Provan D, Stasi R, Newland AC, et al. : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
33) Kroger A, Bahta L, Hunter P (Advisory committee on immunization practices, CDC) : ACIP General Best Practice Guidances for Immunization--altered Immunocompetence. Updated May 4, 2021, Vaccine Recommendations and Guidelines of the ACIP. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html
 
34) UK Health Security Agency : Chapter 6 : Contraindication and special considerations. Last updated 26 October 2017, The Green Book : Information for public health professionals on immunisation, Part 1. https://:www.gov.uk/government/.../Greenbook_chapter_6.
 
35) Ramaswamy K, Hsieh L, Leven E, et al. : Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 165 : 600-605 e4, 2014.
 
36) Bussel JB, de Miguel PG, Despotovic JM, et al. : Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT) : a randomised, multicentre, placebo-controlled study. Lancet Haematol 2 : e315-e325, 2015.
 
37) Grainger JD, Locatelli F, Chotsampancharoen T, et al. : Eltrombopag for children with chronic immune thrombocytopenia (PETIT2) : a randomized multicentre, placebo-controlled trial. Lancet 386 : 1649-1658, 2015.
PubMed
38) Gerrits AJ, Leven EA, Frelinger AL 3rd, et al. : Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood 126 : 1367-1378, 2015.
PubMed
39) Neunert C, Despotovic J, Haley K, et al. : Thrombopoietin Receptor Agonist Use in Children : Data From the Pediatric ITP Consortium of North American ICON2 study. Pediatr Blood Cancer 63 : 1407-1413, 2016.
 
40) 柳澤敦広, 橋本みゆき, 益田大幸, 他 : エルトロンボパグを導入した治療抵抗性慢性ITP女児の1例. 日小児会誌 117 : 175, 2013.
 
41) 森麻希子, 加藤元博, 康勝好, 他 : 慢性ITPに対するエルトロンボパグの使用経験. 日小児会誌 117 : 155, 2013.
 
42) 傍示幸, 飯盛美由紀, 持永早希子, 他 : ロミプロスチムが有効であったエルトロンボパグオラミン抵抗性の特発性血小板減少性紫斑病の1例. 日小児臨薬理会誌 27 : 95, 2014.
 
43) 高橋俊行, 小林良二, 岸本健治, 他 : 小児慢性特発性血小板減少性紫斑病に対するエルトロンボパグの使用経験. 日小児会誌 118 : 1091-1097, 2014.
 
44) 小池和俊, 小宅奈津子, 吉見愛, 他 : 1型糖尿病に合併した慢性免疫性血小板減少性紫斑病に対するeltrombopag治療. 日小児会誌 118 : 424, 2014.
 
45) 坂田謙治, 高瀬浩二郎, 永井攻造, 他 : 小児難治性ITPに対しトロンボポエチン (TPO) 受容体作動薬 (エルトロンボパグ) で治療を行った4例. 日小児会誌 118 : 89, 2014.
 
46) 小池和俊, 吉見愛, 中尾朋平, 他 : 4歳以下の重症慢性免疫性血小板減少性紫斑病 (ITP) 5例に対するeltrombopag治療. 日小児会誌 119 : 287, 2015.
 
47) 森麻希子, 加藤元博, 康勝好, 他 : Eltrombopag からromiplostimへの治療変更が有用であった小児難治性ITP. 臨血 56 : 511-513, 2015.
 
48) Kojima D, Murakami N, Sekiya Y, et al. : Successful management of acute refractory ITP with rituximab and eltrombopag, Jpn J Clin Hematol (abstract) 56 : 1662, 2015.
 
49) 野村武雅, 木部哲也, 横地健治, 他 : 小児慢性ITP に対するエルトロンボパグとロミプロスチムの使用経験. 日小児会誌 120 : 419, 2016.
 
50) Bussel JB, Buchanan GR, Nugent DJ, et al. : A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118 : 28-36, 2011.
PubMed
51) Elalfy MS, Abdelmaksoud AA, Eltonbary KY : Romiplostim in children with chronic refractory ITP : randomized placebo controlled study. Ann Hematol 90 : 1341-1344, 2011.
PubMed
52) Mokhtar GM, Tantawy AA, El Sherif NH : Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets, 23 : 264-273, 2012.
PubMed
53) Escudero Vilaplana V, Aragones JH, Fernandez-Llamazares CM, et al. : Use of romiplostim for primary immune thrombocytopenia in children. Pediatr Hematol Oncol 29 : 197-205, 2012.
PubMed
54) Pasquet M, Aladjidi N, Guiton C, et al. : Romiplostim in children with chronic immune thrombocytopenia (ITP) : the French experience. Br J Haematol 164 : 266-271, 2014.
PubMed
55) Seidel MG, Urban C, Sipurzynski J, et al. : High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia. Br J Haematol 165 : 419-621, 2014.
PubMed
56) Minowa K, Arai K, Kasahara M, et al. : Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis. Pediatr Transplant 18 : E212-E215, 2014.
PubMed
57) Bussel JB, Hsieh L, Buchana GR, et al. : Long-term use of the thrombopoetin-mimeric romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer 62 : 208-213, 2015.
 
58) Mathias SD, Li X, Eisen M, et al. : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents. Pediatr Blood Cancer 63 : 1232-1237, 2016.
PubMed
59) Tarantino MD, Bussel JB, Blanchette VS, et al. : Romiplostim in children with immune thrombocytopenia : a phase 3, randomized, double-blind, placebo-controlled study. Lancet 388 : 45-54, 2016.
PubMed
60) Grainger JD, Bussel JB, Cooper N, et al. : A single-arm, open-label, long-term efficacy and safety study of subcutaneous (SC) romiplostim in children with immune thrombocytopenia. ASH 58th Annual Meeting & Exposition, 868, 2016.
 
61) Bussel JB, Wang X, Lopez A, et al. : Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. Hematology 21 : 257-262, 2016.
PubMed
62) Suntsova EV, Demina IM, Ignatova AA, et al. : Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol 105 : 841-848, 2017.
PubMed
63) Gernsheimer TB, George JN, Aledort LM, et al. : Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 8 : 1372-1382, 2010.
PubMed
64) Vishnu P, Aboulafia DM : Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J Blood Med 7 : 99-106, 2016.
PubMed
65) Tarantino MD, Despotovic JM, Roy J, et al : Safety and efficacy of romiplostim in over 200 children with immune thrombocytopenia (ITP) : Results of integrated database of 5 clinical trials. ASH 60th Annual Meeting & Exposition, 2428, 2018.
 
66) Wong RSM, Saleh MN, Khelif A, et al. : Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag : final results of the EXTEND study. Blood 130 : 2527-2536, 2017.
PubMed
67) Mantadakis E, Buchanan GR : Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 22 : 148-153, 2000.
PubMed
68) Bhatt NS, Bhatt P, Donda K, et al. : Trends of Splenectomy in Pediatric Patients with Immune Thrombocytopenia before and after the ASH 2011 Evidence-Based Practice Guidelines. Blood 130 (Suppl 1) : 676, 2017.
 
69) Mithoowani S, Gregory-Miller K, Goy J, et al. : High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia : a systematic review and meta-analysis. Lancet Haematol 3 : e489-e496, 2016.
PubMed
70) Fujisawa K, Iyori H, Ohkawa H, et al. : A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol 72 : 376-383, 2000.
PubMed
71) Yamazaki T, Shibuta A, Ishii S, et al. : High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. Pediatr Int 59 : 303-308, 2017.
 
72) 藤沢康司, 伊従秀章 : 血小板減少症の治療-小児の血小板減少症とセファランチンR-. 新薬と臨 47 : 97-103, 1998.
 
73) 太田茂, 鈴木淳史, 杉浦康夫, 他 : 小児慢性特発性血小板減少性紫斑病に対する大量ビタミンCおよびセファランチン投与の経験. 日小児血液会誌 7 : 452-456, 1993.
 
74) 桜井信男, 安永幸二郎, 野村武夫, 他 (TJ-137ITP 臨床試験研究会) : 特発性血小板減少性紫斑病 (ITP) に対するTJ-137 ツムラ加味帰脾湯の多施設臨床評価. 臨と研 70 : 345-352, 1993.
 
75) 和田和夫, 小林正行, 南川光三, 他 : 特発性血小板減少性紫斑病に対する加味帰脾湯の使用経験. 漢方医 17 : 383-386, 1993.
 

書評

最近チェックした商品履歴

Loading...